CytoMed Therapeutics Limited (NASDAQ: GDTC)
$2.04
+0.0400 ( +2.00% ) 4.2K
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Market Data
Open
$2.04
Previous close
$2.00
Volume
4.2K
Market cap
$22.62M
Day range
$1.94 - $2.05
52 week range
$1.89 - $5.50
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k/a | Quarterly Reports | 1 | Jun 24, 2024 |
6-k | Quarterly Reports | 1 | Jun 20, 2024 |
6-k | Quarterly Reports | 1 | May 24, 2024 |
6-k/a | Quarterly Reports | 2 | Apr 25, 2024 |
6-k | Quarterly Reports | 2 | Apr 24, 2024 |
20-f | Annual reports | 181 | Apr 22, 2024 |
6-k | Quarterly Reports | 3 | Mar 18, 2024 |
6-k | Quarterly Reports | 3 | Mar 04, 2024 |
6-k | Quarterly Reports | 3 | Jan 29, 2024 |
6-k | Quarterly Reports | 5 | Nov 17, 2023 |